Free Trial
LON:FARN

Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

Faron Pharmaceuticals Oy logo
GBX 202.75 -7.25 (-3.45%)
As of 03/28/2025 12:36 PM Eastern

About Faron Pharmaceuticals Oy Stock (LON:FARN)

Key Stats

Today's Range
202.75
220
50-Day Range
150
212
52-Week Range
85
290
Volume
25,650 shs
Average Volume
20,937 shs
Market Capitalization
£272.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

Remove Ads
Receive FARN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

FARN Stock News Headlines

Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Faron Pharmaceuticals Regulatory News
Faron Pharmaceuticals Reports Promising BEXMAB Trial Results
See More Headlines

FARN Stock Analysis - Frequently Asked Questions

Faron Pharmaceuticals Oy's stock was trading at GBX 207 at the beginning of the year. Since then, FARN stock has decreased by 2.1% and is now trading at GBX 202.75.
View the best growth stocks for 2025 here
.

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:FARN
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-60,233,480.81
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 10.14 per share
Price / Cash Flow
20.00
Book Value
GBX 1,957.36 per share
Price / Book
0.10

Miscellaneous

Free Float
N/A
Market Cap
£272.20 million
Optionable
Not Optionable
Beta
0.36
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:FARN) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners